06:33 AM EDT, 09/02/2025 (MT Newswires) -- Zymeworks ( ZYME ) said Tuesday that it has decided to voluntarily discontinue the clinical development of ZW171, which was designed to target gynecological, thoracic and digestive system cancers.

The company said that its decision was based on results from the dose escalation portion of the phase 1 trial of ZW171 in patients with ovarian cancer and non-small cell lung cancer.

After completing the planned dose escalation cohorts and establishing a maximum tolerated dose, the company decided that "further dose evaluation in the current trial would be unlikely to support a benefit-risk profile consistent with the desired monotherapy target product profile," Zymeworks ( ZYME ) said.

Zymeworks ( ZYME ) shares were down more than 2% in recent Tuesday premarket activity.